PSA mass screening

Is there enough evidence?

Bernardo Rococo, Angelica Grasso, Roman Sosnowski, Paolo Guido dell'Orto, Giancarlo Albo, Erik Castle, Rafael Coelho, Vip Patel, Alex Mottrie

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prostate cancer plays an important role in widely understood aspects of men's health, and is becoming a growing problem in terms of public life. Prostate cancer is one of the most common neoplasms among men. Male patients can live with prostate cancer for a long time so it is important to offer appropriate males adequate diagnostic tools and treatments. Prostate cancer and PSA potentially represent a "pair" of a disease and an appropriate indicator to be used in mass screening, but regardless of that there is still active debate about it. Extensive use of PSA screening has modified epidemiology of the diseases. Randomized controlled studies provided sufficient results regarding a reduction in mortality through PSA mass screening, while all agreed on risks of overdiagnosis and overtreatment. New and accurate screening tools are necessary, along with adequate counseling and risk stratification.

Original languageEnglish
Pages (from-to)4-6
Number of pages3
JournalCentral European Journal of Urology
Volume65
Issue number1
Publication statusPublished - 2012

Fingerprint

Mass Screening
Prostatic Neoplasms
Men's Health
Counseling
Epidemiology
Mortality
Neoplasms
Medical Overuse
Therapeutics

Keywords

  • Prostate cancer
  • Prostate cancer screening
  • PSA

ASJC Scopus subject areas

  • Urology

Cite this

Rococo, B., Grasso, A., Sosnowski, R., dell'Orto, P. G., Albo, G., Castle, E., ... Mottrie, A. (2012). PSA mass screening: Is there enough evidence? Central European Journal of Urology, 65(1), 4-6.

PSA mass screening : Is there enough evidence? / Rococo, Bernardo; Grasso, Angelica; Sosnowski, Roman; dell'Orto, Paolo Guido; Albo, Giancarlo; Castle, Erik; Coelho, Rafael; Patel, Vip; Mottrie, Alex.

In: Central European Journal of Urology, Vol. 65, No. 1, 2012, p. 4-6.

Research output: Contribution to journalArticle

Rococo, B, Grasso, A, Sosnowski, R, dell'Orto, PG, Albo, G, Castle, E, Coelho, R, Patel, V & Mottrie, A 2012, 'PSA mass screening: Is there enough evidence?', Central European Journal of Urology, vol. 65, no. 1, pp. 4-6.
Rococo B, Grasso A, Sosnowski R, dell'Orto PG, Albo G, Castle E et al. PSA mass screening: Is there enough evidence? Central European Journal of Urology. 2012;65(1):4-6.
Rococo, Bernardo ; Grasso, Angelica ; Sosnowski, Roman ; dell'Orto, Paolo Guido ; Albo, Giancarlo ; Castle, Erik ; Coelho, Rafael ; Patel, Vip ; Mottrie, Alex. / PSA mass screening : Is there enough evidence?. In: Central European Journal of Urology. 2012 ; Vol. 65, No. 1. pp. 4-6.
@article{72c6500fc37a40d5b62f73e2fea3320b,
title = "PSA mass screening: Is there enough evidence?",
abstract = "Prostate cancer plays an important role in widely understood aspects of men's health, and is becoming a growing problem in terms of public life. Prostate cancer is one of the most common neoplasms among men. Male patients can live with prostate cancer for a long time so it is important to offer appropriate males adequate diagnostic tools and treatments. Prostate cancer and PSA potentially represent a {"}pair{"} of a disease and an appropriate indicator to be used in mass screening, but regardless of that there is still active debate about it. Extensive use of PSA screening has modified epidemiology of the diseases. Randomized controlled studies provided sufficient results regarding a reduction in mortality through PSA mass screening, while all agreed on risks of overdiagnosis and overtreatment. New and accurate screening tools are necessary, along with adequate counseling and risk stratification.",
keywords = "Prostate cancer, Prostate cancer screening, PSA",
author = "Bernardo Rococo and Angelica Grasso and Roman Sosnowski and dell'Orto, {Paolo Guido} and Giancarlo Albo and Erik Castle and Rafael Coelho and Vip Patel and Alex Mottrie",
year = "2012",
language = "English",
volume = "65",
pages = "4--6",
journal = "Central European Journal of Urology",
issn = "2080-4806",
publisher = "Polish Urological Association",
number = "1",

}

TY - JOUR

T1 - PSA mass screening

T2 - Is there enough evidence?

AU - Rococo, Bernardo

AU - Grasso, Angelica

AU - Sosnowski, Roman

AU - dell'Orto, Paolo Guido

AU - Albo, Giancarlo

AU - Castle, Erik

AU - Coelho, Rafael

AU - Patel, Vip

AU - Mottrie, Alex

PY - 2012

Y1 - 2012

N2 - Prostate cancer plays an important role in widely understood aspects of men's health, and is becoming a growing problem in terms of public life. Prostate cancer is one of the most common neoplasms among men. Male patients can live with prostate cancer for a long time so it is important to offer appropriate males adequate diagnostic tools and treatments. Prostate cancer and PSA potentially represent a "pair" of a disease and an appropriate indicator to be used in mass screening, but regardless of that there is still active debate about it. Extensive use of PSA screening has modified epidemiology of the diseases. Randomized controlled studies provided sufficient results regarding a reduction in mortality through PSA mass screening, while all agreed on risks of overdiagnosis and overtreatment. New and accurate screening tools are necessary, along with adequate counseling and risk stratification.

AB - Prostate cancer plays an important role in widely understood aspects of men's health, and is becoming a growing problem in terms of public life. Prostate cancer is one of the most common neoplasms among men. Male patients can live with prostate cancer for a long time so it is important to offer appropriate males adequate diagnostic tools and treatments. Prostate cancer and PSA potentially represent a "pair" of a disease and an appropriate indicator to be used in mass screening, but regardless of that there is still active debate about it. Extensive use of PSA screening has modified epidemiology of the diseases. Randomized controlled studies provided sufficient results regarding a reduction in mortality through PSA mass screening, while all agreed on risks of overdiagnosis and overtreatment. New and accurate screening tools are necessary, along with adequate counseling and risk stratification.

KW - Prostate cancer

KW - Prostate cancer screening

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=84858019893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858019893&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 4

EP - 6

JO - Central European Journal of Urology

JF - Central European Journal of Urology

SN - 2080-4806

IS - 1

ER -